Experience
Dr. Amrita Ghosh
PG Diploma (Endocrinology, USW,
UK)
PG Diplóma (Clinical Endocrinology and Diabetes, RCP, UK)
Fellowship of Dabetes Research Centre, Chennai
Dr.Ghosh has completed her graduation from Govt. Medical College Nagpur, Post Graduate diploma and fellow ship in Diabetes from M.V Hospital for Diabetes and Professor M.Viswanathan Diabetes Research Centre (WHO collaborating centre) and Post graduate diploma in Clinical Endocrinology and Diabetes, certified by Royal college of Physicians , UK. Her main areas of interest lies in type 1diabetes and new technology related to diabetes management, gestation diabetes. She is actively involved in Type 1 Diabetes advocacy and support groups. She has publication is international journals and member of international bodies.
Our Services
- Diabetes
- Type 1 Diabetes
- Gestational Diabetes
- Obesity
- Thyroid Problems
- Blood Pressure
- Metabolic Syndrome
- Hormonal Health
- PCOS/PCOD Treatment
Current Positions Held
Attending Consultant at Fortis CDOC Hospital for Diabetes and Endocrinology and other allied specialties, Nehru Place, New Delhi
2016–presentMedical Administrator, Fortis CDOC Hospital
IPD In-charge, Fortis CDOC Hospital, New Delhi
Faculty, DMI–Fortis Diabetes Course
Certified Insulin Pump Practitioner
Moderator, T1 Warrior — Type 1 Diabetes Patient Support Group
Earlier Positions Held
Senior Resident
FORTIS CDOC Hospital, New Delhi
2012–2016Junior Resident
M.V. Hospital for Diabetes, Chennai
2010–2012Junior Medical Officer
Public Health Centre, Nancowry Island, A&N Islands
2009–2010Educational Qualification
PG Diploma Endocrinology
University of South Wales, United Kingdom
2019–2020PG Diploma in Clinical Endocrinology and Dia
Royal College of Physician
2017–2018RC (Residential Fellowship of Diabetes Research)
Hospital for Diabetes Chennai (A WHO and IDF collaboration Centre for research)
2010–2012MBBS
Govt. Medical College, Nagpur (Maharashtra University of Health Sciences)
2002–2008Research Publications
1. Ghosh A, Mista A. From abdominal adiposity to liver fibrosis. Expanding promise of semaglutide for Asian Indians. Indian J Gastroenterol. 2005 Oct 10, doi 10.1007512664-025-01881-6. Epub ahead of print. PMID: 41071271.
2. Ghosh A, Gupta R, Misra A. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India. J Diabetes. 2016 Sep.8(5) 738
3. Ghosh A, Misra A "Pokémon Go, Obesity and Diabetes: A Perspective from India", Journal of Diabetes Technology & Therapeutics 18(11), 725-726, Oct 2016.
4. Ghosh A. Gupta R. Dutta A, Singh P, Misra A Sodium-glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes in North India: A 12 Months Prospective Study in Real World Setting. International Journal of clinical practice 2018 Aug vol72, Issue 9
5. Ghosh A, Gupta R, Misra A. Telemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: Guidelines for physicians. Diabetes Metab Syndr. 2020,14(4):273-276. doi: 10.1016/j dsx.2020.04.001
6. Ghosh A. Dutta K, Tyagi K, Gupta R., Misra A. Roadblock in application of telemedicine for diabetes management in India during COVID19 pandemic. Diabetes Metab Syndr. 2020,14(4):577-578. doi: 10.1016/j.dsx 2020.05.010
7. Ghosh A, Arora B, Gupta R, Anoop S, Misra A. Effects of nationwide lockdown during COVID-19 epidemie on lifestyle and other medical issues of patients with type 2 diabetes in north India. Diabetes Metab Syndr. 2020,14(5):917-920. doi: 10.1016/j.dsx 2020.05.044
8. Ghosh A. Anjana RM, Shanthi Rani CS, Jeba Rani S, Gupta R, Jha A, Gupta V, Kuchay MS, Luthra A, Durrani S, Dutta K, Tyagi K, Unnikrishnan R, Srivastava BK, Ramu M, Sastry NG, Gupta PK, Umasankari G, Jayashri R, Mohan V, Misra A. Glycemic parameters in patients with new-onset diabetes during COVID-19 pandemic are more severe than in patients with new-onset diabetes before the pandemic: NOD COVID India Study. Diabetes Metab Syndr. 2020 Dec 29:15(1)215-220
9. Ghosh A, Misra A. Marked hyperglycemia and ketosis in a non-obese patient with new onset diabetes and very mild COVID-19 symptoms: A case report. Diabetes Metab Syndr. 2020 Dec 25,15(1)213-214
10. Ghosh A, Gupta V, Misra A. COVID19 induced acute pancreatitis and pancreatic necrosis in a patient with type 2 diabetes. Diabetes Metab Syndr 2020 Nov-Dec, 14(6):2097-2098
11. Ghosh A, Dutta K, Bhatt SP, Gupta R, Tyagi K, Ansari IA, Venugopal VK, Mahajan H, Pandey RM, Pandey S. Misra A. Dupagliflozin Improves Body Fut Patterning, and Hepatic and Pancreatic Fat in Patients with Type 2 Diabetes in North India. J Clin Endocrinol Metab. 2022 May 17,107(6): e2267-e2275 dot 10 1210/clinem/dgac138. PMID: 35263436
12. Gupta R, Ghosh A, Misra A. Case of acute unilateral emphysematous pyelonephritis and bacteraemia on treatment with canagliflozin. Postgrad Med J. 2018 Dec, 94(1118):714-715
13. Gupta A, Ghosh A. Hyperpigmentation and thickening of skin with callosity formation over dorsum of both feet and healed ulceration over left lateral malleolus in a patient with type 2 diabetes performing prolonged prayers. Diabetes Metab Syndr. 2020,14(3):221-223. doi: 10.1016/j.dsx.2019.12.008
14. Mittal J, Ghosh A, Bhatt SP, Anoop S, Ansari IA, Misra A. High prevalence of post COVID-19 fatigue in patients with teatrol study. Diabetes Metab Syndr. 2021 Nov-Dec, 15(6): 162302. doi: 10.1016/jdsx 2021. 102302. Epub 2021 Sep 24. PMID 6264
16. Tyagi, Ghosh A, Nair D. Dutta K, Singh Bhandari P, Ahmed Ansari 1, Misra A Breakthrough COVID 19 infections after vaccinations in healthcare and other workers in a chronic core medical facility in New Delhi, India. Diabetes Metah Syndr. 2021 May-Jun. 15(3):1007-1008. doi: 10.1016/j des 2021.05.001 Epuh 2021 May 1 PMID 33001805: PMCID PMCR091733.
17. Gupta R. Ghosh A, Singh AK, Minen A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic Diabetes Metab Syndr. 3030,14(3)211-212 doi 10.1016) dsx 2020 03 type 2002
18. Marn A. Ghosh A. Gupta R. Heterogeneity in presentation of hyperglycaemia during COVID-19 pandemic: A proposed classification. Diabetes Metah Syndr. 2021 Jan-Feb, 15(1) 403-406. doi: 10.1016j dsx 2021.01.018. Epub 2021 Jan 31. PMID 33588198, PMCID: PMC7847699
19. Kumar A. Kuchay MS, Ghosh A, Gulati S, Choudhary NS, Dutta D, Sharma P, Vikram NK, Misra A. India-Specific Consermin on MASLD in Type 2 Diabetes: Bridging Global Guidelines to Local Realities. Diabetes Care 2025 Nov 1,48(11):e153-154. doi: 10.2337/dc25-1319. PMID: 41115226
20. Misra A, Sattar N. Ghosh A. Nassar M, Jayawardena R, Gupta R. Type 2 diabetes in South Asians BMJ. 2025 Aug 12,390 079801. doi: 10.1136/bmj-2024-079801 PMID: 40796264
21. Misra A, Vikram NK, Ghosh A, Ranjan P, Gulati S, India Obesity Commission Members. Revised definition of obesity in Asian Indians living in India. Diabetes Metab Syndr. 2025 Jan 15 102989. doi: 10.1016/j.dss. 2024.102989, Epub ahead of print. PMID: 39814628.
22. Singh AK, Gupta R. Ghosh A. Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metah Syndr 2020,14(4) 303-310. doi: 10.1016/j dsx. 2020.04.004
23. Sarveswaran G, Rangamani S, Ghosh A, Bhansali A, Dharmalingam M, Unnikrishnan AG, Kishore Vikram N, Mathur P, Misra A. Management of diabetes mellitus through teleconsultation during COVID-19 and similar scenarios-Guidelines from Indian Council of Medical Research (ICMR) expert group. Diabetes Metab Syndr 2021 Sep-Oct, 15(5) 102242. doi: 10.1016/j dax 2021.102242. Epub 2021 Aug 8. PMID: 34399274, PMCID: PMC8349457
24. Misra A, Kumar A. Kuchay MS, Ghosh A. Gulati S, Choudhary NS, Dutta D, Sharma P, Vikram NK, Delphi Committee. Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes. Diabetes Metab Syndr. 2025 Mar, 19(3): 103209 doi: 10.1016/j dss 2025 103209. Epub 2025 Mar 5. PMID: 40222341
25. Jha A, Misra A, Gupta R, Grosh A. Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases. Diabetes Metab Syndr 2020,14(3)213-216. doi: 10.1016/j.dsx 2020.03.001
26. Sabharwal M. Misra A, Ghosh A, Chopra G. Efficacy of Digitally Supported and Real-Time Self-Monitoring of Blood Glucose-Driven Counseling in Patients with Type 2 Diabetes Mellitus: A Real-World, Retrospective Study in North India. Diabetes Metab Syndr Obes 2022 Jun 5; 15.23-33. doi: 10.2147/DMSO 5345785. PMID 35023937, PMCID: PMC8743499
27. Ghosal S, Arora B, Dutta K, Ghosh A, Sinha B, Misra A Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India. A cohort analysis. Diabetes Metab Syndr. 2020,14(5):949-952. doi: 10.1016/j.dsx.2020.06.020
28. Gupta R, Tyagi K, Anoop S, Ghosh A, Misra A. About 1/3rd of north Indian patients less than 50 years of age with type 2 diabetes have high pulse wave velocity mdicating high risk of atherosclerosis. Diabetes Metab Syndr 2020 Nov-Dec, 14(6) 2205-2210.
29. Gupta R, Gupta A, Shrikhande M, Tyagi K, Ghosh A, Misra A. Marked erythrocytosis during treatment with sodium glucose cotransporter-2 inhibitors-report of two cases. Diabetes Res Clin Pract. 2020, 162:108127. doi: 10.1016/j diabres 2020.108127
30. Gupta R, Kesavadev J, Krishnan G, Agarwal S, Saboo B, Shah M, Mittal A, Durani S, Luthra A, Singhal A, Rasheed M, Rao GVS, Tripathi V, Jha A, Ghosh A. Mohan V. Singh AK, Phatak S, Panicker J, Bhadada SK, Joshi S, Pal It, Mithal A. Vikram N. Misra A. COVID-19 associated mucormycosis: A Descriptive Multisite Study from India. Diabetes Metab Syndr. 2021 Nov-Dec, 15(6) 102322. doi: 10.1016/j dsx 2021.102322. Epub 2021 Oct 27. PMID: 34717135; PMCID: PMC8635309
Role of speaker, panelist and chair person in numerous regional an national conferences including RSSDI